The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A prospective randomized controlled trial comparing 4-weekly versus 3-weekly adjuvant chemotherapy with gemcitabine after curative resection of biliary tract cancer.
Shin Nakahira
No relevant relationships to disclose
Shogo Kobayashi
No relevant relationships to disclose
Atsushi Miyamoto
No relevant relationships to disclose
Junzo Shimizu
No relevant relationships to disclose
Masaki Kashiwazaki
No relevant relationships to disclose
Shigeyuki Ueshima
No relevant relationships to disclose
Yong-Kook, Kim
No relevant relationships to disclose
Toru Kitagawa
No relevant relationships to disclose
Keizo Dono
No relevant relationships to disclose
Masaki Mori
No relevant relationships to disclose
Yuichiro Doki
No relevant relationships to disclose
Hiroaki Nagano
No relevant relationships to disclose